Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Tevogen Q3 2026 Results: Net Loss of $7M, Loss Widens

Tevogen Inc. reported a net loss of $18.2 million for the nine months ended September 30, 2026, compared to $21.6 million in the prior year period. The company continues to operate with a significant stockholders' deficit of $11.3 million and relies on financing activities, including a $3.0 million loan and $3.0 million from pre-funded warrants, to fund its biotechnology and AI initiatives.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-7.0-5.7
EPS (diluted, $ a share)$-1.76$-1.50

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: TVGN. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Tevogen Inc.: key numbers

Share price
$6.22Close, Nov 16
Market cap
$40.5M
Shares outstanding
6.51MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Tevogen Inc.

All →
11:50 AM ET 8-K
Leadership Change

Tevogen Leadership Change

Susan Podlogar resigned from the Board of Directors of Tevogen Inc. effective November 2, 2026. Following the resignation, the Board reduced its size from six to five members and appointed current director Lindee Goh to the Audit Committee.

6:00 AM ET 8-K
Loan & Debt

Tevogen $36M Debt Financing with The Patel Family, LLP

Tevogen Inc. amended its unsecured line of credit with The Patel Family, LLP, extending the borrowing period to May 31, 2029, and fixing the share price for debt repayment at $7.40 per share. Following the amendment, the company issued approximately 1.02 million shares to repay the entire $7.4 million outstanding principal balance and accrued interest, effectively eliminating its current debt liabilities.

Value
$36M
Counterparty
The Patel Family, LLP
Term
through May 2029
4:41 PM ET 8-K
Nasdaq/NYSE Compliance Notice

Tevogen Nasdaq/NYSE Compliance Notice

Tevogen Inc. received written notice from Nasdaq confirming it has regained compliance with the $50 million minimum market value of listed securities requirement under Nasdaq Listing Rule 5450(b)(2)(A). This follows a previous notice regarding the market value of publicly held shares, and with both requirements now satisfied, all related Nasdaq compliance matters are closed.

Counterparty
The Nasdaq Stock Market LLC
5:13 PM ET 8-K
Stock Plan Amendment

Tevogen Stock Plan Amendment

Tevogen Inc. granted performance-based restricted stock awards to its CEO Ryan Saadi (8,000,000 shares) and CFO Kirti Desai (750,000 shares) under the 2024 Omnibus Incentive Plan. Vesting is contingent upon the company achieving a $1.0 billion aggregate revenue threshold by September 30, 2031. The grants are intended to align executive compensation with long-term growth and stockholder value creation.

Term
through Sep 2031

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.